LeonaBio (LONA) Cash & Equivalents (2019 - 2026)

LeonaBio (LONA) has reported Cash & Equivalents for 8 consecutive years, with $32.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 24.26% year-over-year to $32.8 million; the TTM figure through Mar 2026 stood at $32.8 million (up 24.26% YoY), while the FY2025 annual figure was $69.3 million, up 43.02% from the prior year.
• Cash & Equivalents declined to $32.8 million in Q1 2026 per LONA's latest filing, from $69.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $117.8 million in Q1 2022 and bottomed at $19.9 million in Q2 2025.
• Historically, Cash & Equivalents has averaged $73.8 million across 5 years, with a median of $77.8 million in 2024.
• On a YoY basis, Cash & Equivalents climbed as much as 43.02% in 2025 and fell as far as 73.06% in 2025.
• LeonaBio's Cash & Equivalents stood at $96.0 million in 2022, then decreased by 5.61% to $90.6 million in 2023, then sank by 46.53% to $48.4 million in 2024, then jumped by 43.02% to $69.3 million in 2025, then tumbled by 52.61% to $32.8 million in 2026.
• Business Quant data shows LONA's Cash & Equivalents at $32.8 million in Q1 2026, $69.3 million in Q4 2025, and $20.9 million in Q3 2025.